<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683458</url>
  </required_header>
  <id_info>
    <org_study_id>20GermanVasc</org_study_id>
    <nct_id>NCT04683458</nct_id>
  </id_info>
  <brief_title>Analysis of Linked Health Insurance Claims and Clinical Registries to Determine Device Surveillance With Paclitaxel-coated Medical Devices</brief_title>
  <acronym>PacliVasc</acronym>
  <official_title>GermanVasc/MDEpiNet Paclitaxel Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GermanVasc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BARMER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MDEpiNet Verband Deutschland e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GermanVasc/MDEpiNet Paclitaxel Study, aims to use routinely collected data from health&#xD;
      insurance claims and registries. The longitudinal data of Germany's second-largest insurance&#xD;
      fund, BARMER, includes the outpatient and inpatient medical care provided to ≈9.4 million&#xD;
      German citizens (13.2% of Germany's population) involving &gt;21 million hospitalizations&#xD;
      between January 1, 2008, and December 31, 2018. The BARMER cohort is similar to Western&#xD;
      European countries and has been widely used for research projects. A regular random sample&#xD;
      validation of internal and external validity is performed by the Medical Service of the&#xD;
      Health Funds in Germany, and various peer-reviewed validation studies have been previously&#xD;
      published. The GermanVasc clinical registry was implemented in 2018 as EU General Data&#xD;
      Protection Regulation (GDPR) compliant registry platform to process routinely collected&#xD;
      clinical data from more than 35 high-volume vascular centers in Germany. In an ongoing&#xD;
      project of a large multispecialty and multidisciplinary research consortium (RABATT study,&#xD;
      Principal Investigator: PD Dr. Christian-Alexander Behrendt), active surveillance and medical&#xD;
      device evaluation methods were developed. The current study aims to determine the long-term&#xD;
      safety and efficacy of paclitaxel-coated balloons and stents in peripheral arteries. It&#xD;
      further aims to illuminate the underlying differences between the cohorts in randomized&#xD;
      controlled trials (RCT) and real-world data that can possibly explain the diametrically&#xD;
      opposed results in an ongoing international controversy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality after 5-years</measure>
    <time_frame>5-years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of all-cause mortality, myocardial infarction, and stroke after 5-years</measure>
    <time_frame>5-years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of all-cause mortality and major amputation of the lower extremities after 5-years</measure>
    <time_frame>5-years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target limb revascularization after 5-years</measure>
    <time_frame>5-years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incident cancer after 5-years</measure>
    <time_frame>5-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor amputation of the target limb after 5-years</measure>
    <time_frame>5-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major amputation of the target limb after 5-years</measure>
    <time_frame>5-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of optimal pharmacological treatment with antithrombotics, antihypertensives, and lipid-lowering drugs</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">14000</enrollment>
  <condition>Paclitaxel Adverse Reaction</condition>
  <condition>Outcome, Fatal</condition>
  <arm_group>
    <arm_group_label>Paclitaxel-coated devices</arm_group_label>
    <description>Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any drug-coated medical device (e.g., drug-eluting stent, drug-coated balloon).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlls</arm_group_label>
    <description>Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any medical device except drug-coated techniques (e.g., drug-eluting stent, drug-coated balloon).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-coated device</intervention_name>
    <description>The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel</description>
    <arm_group_label>Paclitaxel-coated devices</arm_group_label>
    <other_name>Drug-coated balloon</other_name>
    <other_name>Drug-eluting stent</other_name>
    <other_name>Paclitaxel-coated device</other_name>
    <other_name>Paclitaxel-coated balloon</other_name>
    <other_name>Paclitaxel-eluting stent</other_name>
    <other_name>DES</other_name>
    <other_name>DCB</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients above 39 years who underwent first (index) endovascular revascularisation for&#xD;
        symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic&#xD;
        limb-threatening ischaemia in Germany between 2013 and 2017.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fontaine stage II-IV&#xD;
&#xD;
          -  Diabetic foot syndrome with chronic limb-threatening ischaemia&#xD;
&#xD;
          -  Endovascular revascularisation procedure in the lower limbs&#xD;
&#xD;
          -  Treatment between 2013 and 2017&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hybrid surgery&#xD;
&#xD;
          -  Previous major amputation&#xD;
&#xD;
          -  Previous cancer diagnosis&#xD;
&#xD;
          -  Previous paclitaxel-exposure&#xD;
&#xD;
          -  Previous percutaneous coronary intervention&#xD;
&#xD;
          -  Previous revascularisation of the arteries in the lower limbs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian-Alexander Behrendt, PD Dr.</last_name>
    <phone>+4940741018087</phone>
    <email>ch.behrendt@uke.de</email>
  </overall_contact>
  <link>
    <url>http://germanvasc.de</url>
    <description>Website of the responsible research group</description>
  </link>
  <link>
    <url>http://christianbehrendt.net</url>
    <description>Publication List of the Principal Investigator</description>
  </link>
  <link>
    <url>http://mdepinet.de</url>
    <description>Website of the German chapter of the Medical Device Epidemiology Network</description>
  </link>
  <link>
    <url>http://mdepinet.org</url>
    <description>Website of the US Center of the Medical Device Epidemiology Network</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Christian Behrendt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Paclitaxel</keyword>
  <keyword>Health Insurance Claims</keyword>
  <keyword>Real-World Data</keyword>
  <keyword>Quality Improvement</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

